US-based pharmaceutical startup Cleave Biosciences secured $42m of series A funding on Tuesday from investors including Astellas Venture Management, the corporate venturing division of Japan-based pharmaceutical corporation Astellas.
Also participating were venture capital firms US Venture Partners, 5AM Ventures and Clarus Ventures, and investment firm OrbiMed Advisors.
Cleave was set up to discover cancer treatments based around the molecular structure of each patient’s individual tumour. The funding will be used to support research into molecule discovery and studies of proteins.
